- Conditions
- Pulmonary Artery Hypertension
- Interventions
- reserpine, stellate ganglion block, lidocaine
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Group 2 Pulmonary Hypertension, Heart Failure
- Interventions
- Gradient Denervation System
- Device
- Lead sponsor
- Gradient Denervation Technologies
- Industry
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina + 4 more
- Conditions
- Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
- Interventions
- AZD3427, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • La Jolla, California • New Haven, Connecticut + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Imatinib, Sildenafil, Bosentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Weston, Florida • Mineola, New York
- Conditions
- Heart Failure, Pulmonary Hypertension
- Interventions
- Rivet Shunt
- Device
- Lead sponsor
- NXT Biomedical
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Charlottesville, Virginia
- Conditions
- Hypertension, Pulmonary
- Interventions
- Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ubenimex
- Drug
- Lead sponsor
- Eiger BioPharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • La Jolla, California • Palo Alto, California + 20 more
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- TNX-103
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • Rochester, Minnesota + 4 more
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Interventions
- JK07
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Pemziviptadil (PB1046)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- TNX-103, Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 18
- States / cities
- Alexander City, Alabama • Tamarac, Florida • Mount Prospect, Illinois + 15 more
- Conditions
- Pulmonary Hypertension, Familial Persistent, of the Newborn
- Interventions
- placebo, iv sildenafil
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 0 Days to 4 Days
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AIR001 (sodium nitrite inhalation solution)
- Drug
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 17
- States / cities
- La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
- Conditions
- Pulmonary Hypertension
- Interventions
- TNX-103, Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 32 more
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 43
- States / cities
- Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ubenimex, placebo
- Drug · Other
- Lead sponsor
- Eiger BioPharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more
- Conditions
- Pulmonary Hypertension Due to Left Heart Disease
- Interventions
- Treprostinil Diolamine
- Drug
- Lead sponsor
- Mardi Gomberg -Maitland MD, MSc
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- APD811, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AIR001
- Drug
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 17
- States / cities
- La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
- Interventions
- Inhaled Nitric Oxide
- Drug
- Lead sponsor
- Geno LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
- Conditions
- Pulmonary Artery Hypertension
- Interventions
- GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more